About ENGOT

The European Network for Gynaecological Oncological Trial groups (ENGOT) is a research network of the European Society of Gynaecological Oncology (ESGO) and was founded in Berlin on 29 October 2007.

Currently, ENGOT consists of 21 trial groups from 33 European countries that perform cooperative clinical trials.

ENGOT is led by two chairs. At this moment, the clinical chair is Prof. Isabelle Ray-Coquard from France and the operational chair is Dr. Elena Biagioli from Italy.

The chairs are changed every two years. The past chairs were Prof. Nicoletta Colombo from Italy and Dr. Karen Verhoeven from the Netherlands.

Mission Statement

ENGOT is a platform that guarantees that the European spirit and culture is incorporated into the medical progress in gynaecological oncology, and that all European patients and countries can participate in an active way in clinical research and progress.
The ultimate goal is to bring the best treatment to gynaecological cancer patients through the best science, and enabling every patient in every European country to access a clinical trial.

→ View the ENGOT Bylaws. 

Activities

As a network of national and regional clinical trial units, ENGOT coordinates and promotes clinical trials within Europe on patients with gynaecological cancer.

This coordination is particularly relevant for academic clinical trials, translational research, research on rare diseases, and for clinical trials sponsored by the industry to perform multinational studies in Europe.

The ENGOT Assembly further set up the following objectives and strategies:

• Incorporate Translational Research into clinical trials and develop a Early Drug Development network
• Harmonize operational aspects and improve quality of trials
• Provide teaching and mentoring (physician and admin) in order to improve and disseminate the knowledge of conducting clinical trials
• Increase collaboration of all groups